Parnaparin: Difference between revisions
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
No edit summary |
||
| Line 25: | Line 25: | ||
}} | }} | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Parnaparin''' is an antithrombotic agent. It is a low molecular weight hepain. | '''Parnaparin''' is an antithrombotic agent. It is a low molecular weight hepain. | ||
==External | ==External Links== | ||
* {{MeshName|parnaparin}} | * {{MeshName|parnaparin}} | ||
==Additional Resource== | ==Additional Resource== | ||
* {{cite journal |author=Maugeri N, Di Fabio G, Barbanti M, de Gaetano G, Donati MB, Cerletti C |title=Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood |journal=Thromb. Haemost. |volume=97 |issue=6 |pages=965-73 |year=2007 |pmid=17549299 |doi=}} | |||
==References== | |||
{{reflist|2}} | |||
{{Antithrombotics}} | {{Antithrombotics}} | ||
[[Category:Drugs]] | [[Category:Drug]] | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Anticoagulants]] | |||
Latest revision as of 00:49, 26 July 2014
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| CAS Number | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
|
WikiDoc Resources for Parnaparin |
|
Articles |
|---|
|
Most recent articles on Parnaparin |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Parnaparin at Clinical Trials.gov Clinical Trials on Parnaparin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Parnaparin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Parnaparin Discussion groups on Parnaparin Patient Handouts on Parnaparin Directions to Hospitals Treating Parnaparin Risk calculators and risk factors for Parnaparin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Parnaparin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Parnaparin is an antithrombotic agent. It is a low molecular weight hepain.
External Links
- parnaparin at the US National Library of Medicine Medical Subject Headings (MeSH)
Additional Resource
- Maugeri N, Di Fabio G, Barbanti M, de Gaetano G, Donati MB, Cerletti C (2007). "Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood". Thromb. Haemost. 97 (6): 965–73. PMID 17549299.
References
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- CS1 maint: Multiple names: authors list
- Drug
- Cardiovascular Drugs
- Anticoagulants